From a scientific discovery to a pharmaceutical product: The EVASIN project

CAMARGO, A.C.M.(1)

(1)Center for Applied Toxinology (CAT/CEPID-FAPESP)

A Research Cooperation Relationship has been established between Coinfar (Brazilian Pharmaceutical Industries Consortium - Biolab/Sanus, Biosintetica and União Química), Uniemp (Instituto Universidade Empresa), Fapesp and the CAT (Center for Applied Toxinology - CEPID-Fapesp) in order to develop an anti-hypertensive product named EVASIN (Endogenous Vasopeptide Inhibitor), which derived from scientific research on the Bothrops jararaca venom. The Parties agreed on a first project to be carried out “Project EVASINs”, which relates to advanced results and related research based on the patent number PI0101088-3, filed at the Brazilian Institute of Industrial Property – INPI. This project gives us the chance to discuss the potential of animal and microbial toxins for the development of pharmaceutical products, the interests of the Brazilian Pharmaceutical Industries, the gaps existing for the development of a drug from natural substances, the need for specialized management and the strategic steps to be undertaken. We will be talking also about the establishment of an agency, named AGIF (Agência de Gestão da Inovação Farmacêutica), its general profile and aims.

CORRESPONDENCE TO:

ANTONIO CARLOS MARTINS DE CAMARGO, Rua Murajuba ,125, São Paulo, SP, CEP: 05467-010, Brasil, Email: camur@macbbs.com.br